One-Pot Hydrothermal Preparation of Fe3O4 Decorated Graphene for Microwave Absorption

Fe3O4 decorated graphene was synthesized for electromagnetic wave absorption via a facile one-pot hydrothermal approach. The structure and morphology of the as-prepared nanomaterials were systematically investigated. The graphene oxide (GO) was reduced and Fe3O4 nanoparticles were evenly decorated on the surface of reduced graphene oxide (rGO) nanosheets. The average particle size of Fe3O4 nanoparticles is about 15.3 nm. The as-prepared rGO-Fe3O4 nanocomposites exhibited a good microwave absorption performance because of the combination of graphene and magnetic Fe3O4. When the thicknesses are 1.6 mm and 6.5 mm, the reflection loss (RL) values are up to −34.4 dB and −37.5 dB, respectively. The effective bandwidths are 3.8 and 1.9 GHz

ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization

We report here the identification and characterization of a protein, ERIS, an endoplasmic reticulum (ER) IFN stimulator, which is a strong type I IFN stimulator and plays a pivotal role in response to both non–self-cytosolic RNA and dsDNA. ERIS (also known as STING or MITA) resided exclusively on ER membrane. The ER retention/retrieval sequence RIR was found to be critical to retain the protein on ER membrane and to maintain its integrity. ERIS was dimerized on innate immune challenges. Coumermycin-induced ERIS dimerization led to strong and fast IFN induction, suggesting that dimerization of ERIS was critical for self-activation and subsequent downstream signaling

Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial

Abstract Backgrounds Urokinase (UK) 2 200 U/kg·h for 12 hours infusion(UK-12 h)is an ACCP recommended regimen in treating acute pulmonary embolism (PE). It is unclear whether this dose and time can be reduced further. We compared the efficacy and safety of 20, 000 U/kg for 2 hours (UK-2 h) with the UK-12 h regime in selected PE patients. Methods A randomized trial involving 129 patients was conducted. Patients with acute PE were randomly assigned to receive either UK-12 h (n = 70), or UK-2 h (n = 59). The efficacy was determined by the improvement of right heart dysfunction and perfusion defect at 24 h and 14 d post UK treatment. The bleeding incidence, death rate and PE recurrence were also evaluated. Results Similarly significant improvements in right heart dysfunction and lung perfusion defects were observed in both groups. Overall bleeding incidents were low in both groups. Major bleeding directly associated with UK infusion occurred in one patient in the UK-2 h group and one in the UK-12 h group. Mortality rates were low, with one reported fatal recurrent in the UK-12 h group and none in the UK-2 h group. When the rate of bleeding, death and PE recurrence were compared separately in the hemodynamic instability and the massive anatomic obstruction subgroups, no significant difference was found. Conclusions The UK-2 h regimen exhibits similar efficacy and safety as the UK-12 h regimen for acute PE. Trial Registration Clinical trial registered with http://clinicaltrials.gov/ct2/show/NCT00799968 (Identifier: NCT 00799968)</p